Tamsulosin

Generic Name: Tamsulosin

Brand Names: Flomax, Jalyn

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₈N_₂O_₅S

CAS Number: 106133-20-4

Unique Ingredient Identifier: G3P28OML5I

Background: Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common. It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy. Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow. Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.

Tamsulosin was first approved by the FDA on April 15, 1997.

Indication: Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.

Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.

Associated Conditions: Benign Prostatic Hyperplasia (BPH), Benign Prostatic Hypertrophy, Bladder Outlet Obstruction, Ureteral Calculus

Associated Therapies: -

Clinical Trials

Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH

Phase 3

Terminated

Conditions: Lower Urinary Tract Symptoms

Interventions: Drug: NX-1207
Drug: Tamsulosin

First Posted Date: 2013-12-06

Last Posted Date: 2022-05-26

Lead Sponsor: RECORDATI GROUP

Target Recruit Count: 104

Registration Number: NCT02003742

Locations: 🇩🇪
Klinikum der Ludwig-Maximilians-universität München, Munich, Germany
🇮🇹
Vita e Salute University, Department of Urology, Istituto Scientifico Ospedale San Raffaele, Milan, Italy
🇵🇱
Niepubliczny Zaklad Opieki Zdrowotnej Specjalista, Kutno, Poland

and more 2 locations

A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin

Phase 1

Completed

Conditions: EC905
Pharmacokinetics
Healthy Subjects

Interventions: Drug: EC905
Drug: solifenacin
Drug: tamsulosin

First Posted Date: 2013-10-01

Last Posted Date: 2014-05-29

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 30

Registration Number: NCT01953887

Locations: 🇬🇧
Parexel, London, United Kingdom

Comparison of Tamsulosin and Solifenacin in Treatment of Ureteral Stent Symptoms

Phase 4

Completed

Conditions: Relieve of Ureteral Stent Symptoms

Interventions: Drug: Control
Drug: Tamsulosin
Drug: Solifenacin

First Posted Date: 2013-06-19

Last Posted Date: 2015-11-25

Lead Sponsor: Mansoura University

Target Recruit Count: 131

Registration Number: NCT01880619

Locations: 🇪🇬
Urology and Nephrology Center, Mansoura, Egypt

Tamsulosin for Urinary Retention in Hospitalized Older Women

Phase 3

Terminated

Conditions: Urinary Retention

Interventions: Drug: Tamsulosin (0.4 mg/j)
Drug: Placebo

First Posted Date: 2012-12-12

Last Posted Date: 2014-10-02

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 34

Registration Number: NCT01747993

Locations: 🇫🇷
Service de médecine interne, Hôpital Tenon, Paris, France

Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction

Phase 4

Completed

Conditions: Ureteral Obstruction

Interventions: Drug: Tamsulosin
Drug: Tolterodine ER

First Posted Date: 2012-12-05

Last Posted Date: 2019-07-10

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 181

Registration Number: NCT01741454

Locations: 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States

Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients

Phase 4

Conditions: Benign Prostate Hyperplasia

Interventions: Drug: Tamsulosin
Drug: Finasteride
Drug: Placebo

First Posted Date: 2012-11-29

Last Posted Date: 2014-05-14

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 545

Registration Number: NCT01736033

Locations: 🇰🇷
Chungbuk National University Hospital, Cheongju, Chungbuk, Korea, Republic of
🇰🇷
Eulji General Hospital, Seoul, Korea, Republic of
🇰🇷
Hallym University Sacred Heart Hospital, Anyang, Gyeoggi, Korea, Republic of

and more 8 locations